Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

Süssmuth, SD

doi:10.1016/s0304-3940(03)01112-1

Cited by 15 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in contrast with previous studies that showed elevated CSF levels of both tau and S100B decreased levels of Aβ 42 in patients with ALS [5,14,16]. This apparent discrepancy is most probably due to differences in the control groups used.…”

Section: Discussioncontrasting

confidence: 96%

CSF neurofilament protein analysis in the differential diagnosis of ALS

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 96%

CSF neurofilament protein analysis in the differential diagnosis of ALS

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Degeneration of the large-caliber axons (Brettschneider et al 2006c;Rosengren et al 1996) Tau protein : Axonal degeneration (Süssmuth et al 2003) Transglutaminases activity (TGases)…”

Section: Neurofilament Light Chain (Nfl)mentioning

confidence: 99%

“…Another biomarker of axonal degeneration, Tau protein, is elevated in the early clinical phase, and its CSF concentration seems to stabilize in the later stages (Süssmuth et al 2003).…”

Section: Neuroaxonal Degeneration Markers In Csfmentioning

confidence: 99%

CSF markers in amyotrophic lateral sclerosis

et al. 2012

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS, 'Lou Gehrig disease') is the most common, progressive, neurodegenerative, motor neuron disease, causing damage to upper and lower motor neurons, leading to paralysis and death within 3-5 years. Majority of ALS cases are sporadic ALS (SALS) and only 5-10 % of cases are familial ALS (FALS). Pathogenesis of ALS is complicated and still unclear, including genetic, glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neurofilament accumulation, impaired trophic support, altered glial function, viral infection, immune imbalance and impairment of the blood-brain, blood-spinal cord and blood-cerebrospinal fluid barriers (BBB/BSCB/BCSFB). The CSF analysis is still one of the basic laboratory tools and might reflect pathophysiological alterations in the course of the disease and could provide an insight into disease pathomechanisms. The most important aim of its analysis is evaluation of blood-CSF barrier, which is altered in 46 % of ALS patients. The CSF biomarkers may give insight into ALS pathophysiology and may be useful for early, presymptomatic diagnosis, therapeutic monitoring and the development of new therapeutic strategies. This review summarizes the general concepts of biomarkers in CSF of ALS patients and their potential usefulness in further research.

show abstract

“…Elevated levels of S-100B have also been reported in neurodegenerative diseases like AD [10], frontotemporal dementia [11,12] and amyotrophic lateral sclerosis [13]. High levels were reported in Creutzfeldt-Jakob disease and could even be seen in serum samples [14].…”

Section: Introductionmentioning

confidence: 97%

Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

Mollenhauer

Cepek

Bibl³

et al. 2005

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

The intra vitam diagnosis of dementia with Lewy bodies (DLB) is still based on clinical grounds. So far no technical investigations have been available to support this diagnosis. As for tau protein and β-amyloid_(1–42) (Aβ42), promising results for the diagnosis of Alzheimer’s disease (AD) have been reported; we evaluated these markers and S-100B protein in cerebrospinal fluid (CSF), using a set of commercially available assays, of 71 patients with DLB, 67 patients with AD and 41 nondemented controls (NDC) for their differential diagnostic relevance. Patients with DLB showed significantly lower tau protein values compared to AD but with a high overlap of values. More prominent differences were observed in the comparison of DLB patients with all three clinical core features and AD patients. Aβ42 levels were decreased in the DLB and AD groups versus NDC, without significant subgroup differences. S-100B levels were not significantly different between the groups. Tau protein levels in CSF may contribute to the clinical distinction between DLB and AD, but the value of the markers is still limited especially due to mixed pathology. We conclude that more specific markers have to be established for the differentiation of these diseases.

show abstract

Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

Cited by 15 publications

References 0 publications

CSF neurofilament protein analysis in the differential diagnosis of ALS

CSF neurofilament protein analysis in the differential diagnosis of ALS

CSF markers in amyotrophic lateral sclerosis

Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

Contact Info

Product

Resources

About